Dactolisib tosylate is under clinical development by Adicet Bio and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase II drugs for Coronavirus Disease 2019 (COVID-19) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dactolisib tosylate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dactolisib tosylate overview
RTB-101 is under development for the treatment of aging-related immunosenescence, illness associated with respiratory tract infection, aging-related organ failure/dysfunction, TORC1 / autophagy-related diseases, Parkinson's disease, infections including urinary tract infections, neuroblastoma, HER2 positive metastatic breast cancer and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is a small molecule administered by oral route. The drug candidate acts by targeting P13K and mTORC1.
It was also under development for solid tumors such as hormone receptor positive, HER2 negative, metastatic breast cancer, advanced or metastatic breast cancer, pancreatic neuroendocrine tumors, transitional cell carcinoma, advanced renal cell carcinoma (RCC), advanced or metastatic endometrial cancer, metastatic hormone-refractory prostate cancer, heart failure with preserved ejection fraction, and perivascular epithelioid cell tumors.
Adicet Bio overview
Adicet Bio is a clinical-stage biotechnology company. It primarily focuses on the discovery and development of allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company’s product candidate is ADI-001, an investigational allogeneic gamma delta CAR T cell therapy that targets B-cells via an anti-CD20 CAR. Adicet’s products are designed for patients suffering from autoimmune diseases, solid tumors, and hematological malignancies. It also develops ADI-002, used for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. The company operates in the US. Adicet Bio is headquartered in Boston, Massachusetts, the US.
For a complete picture of Dactolisib tosylate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
